Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells 3,290 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 3,290 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $25.00, for a total transaction of $82,250.00. Following the completion of the transaction, the insider now owns 24,592 shares in the company, valued at approximately $614,800. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Christine Ring also recently made the following trade(s):

• On Tuesday, October 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80.
• On Tuesday, September 3rd, Christine Ring sold 9,050 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.94, for a total transaction of $225,707.00.
• On Monday, August 26th, Christine Ring sold 9,870 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $246,848.70.
• On Thursday, August 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $21.43, for a total transaction of $123,436.80.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $24.72 on Friday. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $26.43. The firm has a market capitalization of $1.22 billion, a P/E ratio of -8.47 and a beta of 2.22. The company’s 50 day moving average price is $23.64 and its two-hundred day moving average price is $19.50.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current year.

Analyst Ratings Changes

NRIX has been the subject of a number of recent research reports. Royal Bank of Canada cut their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday. Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 price objective for the company. Truist Financial initiated coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price objective for the company. Barclays boosted their price objective on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Finally, Robert W. Baird initiated coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective for the company. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.71.

Institutional Trading of Nurix Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Nurix Therapeutics during the first quarter valued at $123,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares during the last quarter. Dark Forest Capital Management LP bought a new position in shares of Nurix Therapeutics during the second quarter valued at $201,000. Finally, ProShare Advisors LLC raised its stake in shares of Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after acquiring an additional 998 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.